China · Delayed Price · Currency is CNY Enwei Pharmaceutical Statistics
Total Valuation
SHE:301331 has a market cap or net worth of CNY 2.44 billion. The enterprise value is 2.16 billion.
| Market Cap | 2.44B |
| Enterprise Value | 2.16B |
Important Dates
The last earnings date was Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | May 28, 2026 |
Share Statistics
SHE:301331 has 101.88 million shares outstanding. The number of shares has increased by 5.45% in one year.
| Current Share Class | 101.88M |
| Shares Outstanding | 101.88M |
| Shares Change (YoY) | +5.45% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 4.16% |
| Float | 32.23M |
Valuation Ratios
The trailing PE ratio is 66.85.
| PE Ratio | 66.85 |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| PB Ratio | 2.35 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | 35.90 |
| P/OCF Ratio | 20.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.67, with an EV/FCF ratio of 31.78.
| EV / Earnings | 56.78 |
| EV / Sales | 2.59 |
| EV / EBITDA | 23.67 |
| EV / EBIT | 50.52 |
| EV / FCF | 31.78 |
Financial Position
The company has a current ratio of 4.35, with a Debt / Equity ratio of 0.20.
| Current Ratio | 4.35 |
| Quick Ratio | 3.56 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 2.24 |
| Debt / FCF | 3.00 |
| Interest Coverage | 20.88 |
Financial Efficiency
Return on equity (ROE) is 3.58% and return on invested capital (ROIC) is 4.42%.
| Return on Equity (ROE) | 3.58% |
| Return on Assets (ROA) | 1.81% |
| Return on Invested Capital (ROIC) | 4.42% |
| Return on Capital Employed (ROCE) | 3.42% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | 552,460 |
| Profits Per Employee | 25,173 |
| Employee Count | 1,501 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, SHE:301331 has paid 10.56 million in taxes.
| Income Tax | 10.56M |
| Effective Tax Rate | 21.85% |
Stock Price Statistics
The stock price has decreased by -25.12% in the last 52 weeks. The beta is 0.56, so SHE:301331's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -25.12% |
| 50-Day Moving Average | 21.76 |
| 200-Day Moving Average | 24.30 |
| Relative Strength Index (RSI) | 63.48 |
| Average Volume (20 Days) | 3,954,910 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301331 had revenue of CNY 829.24 million and earned 37.78 million in profits. Earnings per share was 0.36.
| Revenue | 829.24M |
| Gross Profit | 421.58M |
| Operating Income | 42.47M |
| Pretax Income | 48.35M |
| Net Income | 37.78M |
| EBITDA | 89.34M |
| EBIT | 42.47M |
| Earnings Per Share (EPS) | 0.36 |
Balance Sheet
The company has 481.09 million in cash and 202.72 million in debt, with a net cash position of 278.37 million or 2.73 per share.
| Cash & Cash Equivalents | 481.09M |
| Total Debt | 202.72M |
| Net Cash | 278.37M |
| Net Cash Per Share | 2.73 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 10.00 |
| Working Capital | 660.59M |
Cash Flow
In the last 12 months, operating cash flow was 119.19 million and capital expenditures -51.69 million, giving a free cash flow of 67.50 million.
| Operating Cash Flow | 119.19M |
| Capital Expenditures | -51.69M |
| Depreciation & Amortization | 46.87M |
| Net Borrowing | 9.28M |
| Free Cash Flow | 67.50M |
| FCF Per Share | 0.66 |
Margins
Gross margin is 50.84%, with operating and profit margins of 5.12% and 4.56%.
| Gross Margin | 50.84% |
| Operating Margin | 5.12% |
| Pretax Margin | 5.83% |
| Profit Margin | 4.56% |
| EBITDA Margin | 10.77% |
| EBIT Margin | 5.12% |
| FCF Margin | 8.14% |
Dividends & Yields
This stock pays an annual dividend of 1.03, which amounts to a dividend yield of 4.30%.
| Dividend Per Share | 1.03 |
| Dividend Yield | 4.30% |
| Dividend Growth (YoY) | 472.22% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 283.05% |
| FCF Payout Ratio | 155.45% |
| Buyback Yield | -5.45% |
| Shareholder Yield | -1.12% |
| Earnings Yield | 1.50% |
| FCF Yield | 2.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on May 23, 2024. It was a forward split with a ratio of 1.48.
| Last Split Date | May 23, 2024 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
SHE:301331 has an Altman Z-Score of 5.41 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.41 |
| Piotroski F-Score | 5 |